Salarius Pharmaceuticals, Inc. Quarterly Debt-to-equity in % from Q3 2015 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Salarius Pharmaceuticals, Inc. quarterly Debt-to-equity history and growth rate from Q3 2015 to Q2 2024.
  • Salarius Pharmaceuticals, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 34.7 %, a 8.42% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 34.7 -3.19 -8.42% Jun 30, 2024
Q1 2024 36.3 +13.2 +57.1% Mar 31, 2024
Q4 2023 46.4 +33 +246% Dec 31, 2023
Q3 2023 48.4 +39.9 +474% Sep 30, 2023
Q2 2023 37.9 +32 +542% Jun 30, 2023
Q1 2023 23.1 +18.5 +403% Mar 31, 2023
Q4 2022 13.4 +9.28 +225% Dec 31, 2022
Q3 2022 8.43 +3.46 +69.6% Sep 30, 2022
Q2 2022 5.89 -0.49 -7.67% Jun 30, 2022
Q1 2022 4.59 -3.65 -44.3% Mar 31, 2022
Q4 2021 4.13 -7.47 -64.4% Dec 31, 2021
Q3 2021 4.97 -9.47 -65.6% Sep 30, 2021
Q2 2021 6.39 -15 -70.2% Jun 30, 2021
Q1 2021 8.23 -20.3 -71.1% Mar 31, 2021
Q4 2020 11.6 -32.2 -73.5% Dec 31, 2020
Q3 2020 14.5 -119 -89.2% Sep 30, 2020
Q2 2020 21.4 +4.32K Jun 30, 2020
Q1 2020 28.5 +728 Mar 31, 2020
Q4 2019 43.8 +302 Dec 31, 2019
Q3 2019 133 +321 Sep 30, 2019
Q2 2019 -4.3K -4.36K -6656% Jun 30, 2019
Q1 2019 -700 -727 -2682% Mar 31, 2019
Q4 2018 -258 -273 -1836% Dec 31, 2018
Q3 2018 -188 -197 -2187% Sep 30, 2018
Q2 2018 65.5 +58.2 +797% Jun 30, 2018
Q1 2018 27.1 +21.4 +371% Mar 31, 2018
Q4 2017 14.9 +9.82 +195% Dec 31, 2017
Q3 2017 9.01 +4.82 +115% Sep 30, 2017
Q2 2017 7.31 +3.83 +110% Jun 30, 2017
Q1 2017 5.75 +2.77 +93.1% Mar 31, 2017
Q4 2016 5.04 +2.55 +103% Dec 31, 2016
Q3 2016 4.19 +1.48 +54.6% Sep 30, 2016
Q2 2016 3.48 Jun 30, 2016
Q1 2016 2.98 Mar 31, 2016
Q4 2015 2.48 Dec 31, 2015
Q3 2015 2.71 Sep 30, 2015
* An asterisk sign (*) next to the value indicates that the value is likely invalid.